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Abstract
Introduction: Diabetes mellitus (DM) and tuberculosis (TB) are of great public health importance globally, especially in Sub-
Saharan Africa. Tuberculosis is the third cause of death among subjects with non-communicable diseases. DM increases risk of 
progressing from latent to active tuberculosis. The study aimed to ascertain yield of TB cases and the number needed to screen 
(NNS) among DM patients.
Material and methods: A cross-sectional study was conducted at 10 health facilities with high DM patient load and readily 
accessible DOTS center in 6 states of southern region of Nigeria over a period of 6 months under routine programme conditions. 
All patients who gave consent were included in the study. Yield and NNS were calculated using an appropriate formula. 
Results: 3 457 patients were screened with a mean age (SD) of 59.9 (12.9) years. The majority were male, 2 277 (65.9%). Overall 
prevalence of TB was 0.8% (800 per 100 000). Sixteen (0.5%) were known TB cases (old cases). There were 221 presumptive 
cases (6.4%) out of which 184 (83.3%) were sent for Xpert MTB/Rif assay. Eleven (0.3%) new cases of TB were detected, giving 
additional yield of 40.7% and the number needed to screen (NNS) of 315. All the 11 patients were placed on anti-TB treatment.
Conclusions: The prevalence of TB among DM patients was higher than in the general population. The yield was also good and 
comparable to other findings. This underscores the need for institute active screening for TB among DM patients. Further stu-
dies are recommended to identify associated factors to guide policy makers in planning and development of TB-DM integrated 
services. 
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Introduction
Diabetes mellitus (DM) and tuberculosis 
(TB) are major lethal diseases of great public 
health importance globally [1]. This is the most 
visible in Sub-Saharan Africa (SSA) due to the 
converging epidemics of both communicable and 
non-communicable diseases. The World Health 
Organization (WHO) has identified DM as a global 
epidemic. The relationship between diabetes and 
tuberculosis as well as their synergistic role in 
causing human disease may be the next challenge 
for global tuberculosis control [2]. 
Diabetes prevalence is increasing globally, 
especially in low- and middle-income countries 
due to ageing, population growth, rapid econo-
mic, social, and lifestyle changes [3, 4]. About 
422 million people worldwide were living with 
diabetes in 2014 [5]. The global prevalence of 
diabetes was estimated to be 8.5% among adults 
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aged 18 years and above [5]. In 2012, diabetes 
was the direct cause of 1.5 million deaths [5]. 
Eighty percent (80%) of these people live in low- 
and middle-income countries, including Nigeria 
where TB prevalence is equally high. This is also 
where 80% of all deaths due to DM occur [5]. 
About 10–15% of global TB cases are linked to 
diabetes [6]. Diabetes mellitus has recently emer-
ged as risk factor for developing active TB [7]. 
Diabetes triples a person’s risk of developing TB 
[8–11]. The global economic burden of diabetes 
is enormous. In Africa, the mean annual cost for 
diabetes care ranges between $2 144 and $11 430 
(direct costs $876–1 220) [12]. 
Tuberculosis ranks as the second leading 
cause of death from an infectious disease globally 
next to the human immunodeficiency virus (HIV). 
DM and TB comorbidities complicate tuberculo-
sis management and negatively influence its 
treatment outcome [13, 14]. In 2014, 9.6 million 
people fell ill with TB, 1.5 million died from TB 
and one in three individuals in the world was 
infected with latent TB [5]. The World Health Or-
ganization (WHO) reported that in 2017, globally 
there were estimated 10.0 million incident cases 
of TB (range, 9.0–11.1 million), which translates 
to 133 cases (range, 120–148) per 100 000 popu-
lation. Most of these cases in 2017 occurred in 
Asia (44%) and the African Region (24%) [15]. In 
Nigeria, tuberculosis is still a grave public health 
problem. It is associated with huge economic bur-
den just as in other low-income countries [16–18]. 
In Nigeria, despite the National TB and Leprosy 
Control Programme (NTBLCP) reporting 94 604 
cases in 2012, this number only represents 51% 
of the cases estimated to have occurred in the 
country that year [19]. In 2017, the incidence of 
TB in Nigeria was 418 cases (range 273–594) [15].
The presence of DM alone does not justify 
screening or treatment of latent TB infection (LTBI). 
However, when combined with other risk factors 
for TB, the presence of DM may be sufficient to 
justify screening and treatment of LTBI, even in 
a low TB incidence setting [20]. The Sustainable 
Development Goals (SDGs) among other targets, 
made ending the global TB epidemic a priority. 
To achieve this, new strategies need to be em-
ployed. Passive case finding which used to be the 
norm whereby patients present themselves for TB 
screening seems not yielding desired result. Active 
case finding (ACF) is believed to contribute to the 
earlier detection of persons with TB. This will 
lead to early initiation of treatment, better therapy 
outcomes for individuals and ultimately, it will 
reduce transmission in the community [21–23].
The World Health Organization and the 
Union have launched a new ‘Collaborative Fra-
mework for the care and control of Diabetes and 
Tuberculosis’with one of the most important 
activities being the routine implementation 
of bi-directional screening of the two diseases 
[24]. In Nigeria, there are no policies identifying 
DM patients with TB symptoms, or minimi-
sing the time spent by patients with probable 
DM-TB co-morbidity in the diabetes clinics. In 
addition, evidence to inform the development of 
interventions to address the TB burden among 
DM patients is crucial but lacking. Moreover, 
the methods of screening, recording and repor-
ting DM and TB co-morbidity in routine health 
care settings are not well determined, and these 
knowledge gaps need to be addressed. There is 
a need for relevant stakeholders, including: WHO, 
National TB and Leprosy Control Programme and 
government agencies/departments responsible 
for non-communicable diseases to review and 
discuss linkages between DM and TB — hence 
the need for bidirectional screening and the WHO 
Union Collaborative Framework. A multicenter, 
unidirectional study to assess the burden of dia-
betes mellitus among TB patients was recently 
completed in 6 selected states in southern Nigeria 
the results of which have been published [25]. 
The study seeks to address the second arm, i.e. 
intensified TB screening among patients with 
diabetes mellitus. The feasibility of the screening 
(DM patients for TB), burden and challenges will 
be evaluated within routine health care services 
to inform policy change and develop generic 
protocols for its implementation. 
Screening persons with DM for TB could be 
one of the strategies for early and increased TB 
case detection in Nigeria. These informed the 
programme implementation of active case finding 
through screening to ascertain incidence, yield, 
number needed to screen (NNS) for a case of TB 
among DM patients.
Material and methods
Study area
The study was conducted in the southern 
region of Nigeria spanning through all the 
3 geopolitical zones and involving 6 states (two 
from each geopolitical zone) namely; Ogun, 
Ondo, Edo, Delta, Enugu and Abia States. Dia-
betes clinics of selected health facilities with 
high DM patient load and readily accessible 
DOTS centre were selected in each state for the 
study. This region hosts the major oil producing 
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states. They engage in farming, fishing, mining, 
trading as well as civil/public services. There 
are well established health centres, including 
tertiary, secondary and primary facilities that 
care for patients, including those with DM and 
TB. However, 10 health clinics were used for the 
study. These were the major centres caring for 
both diseases in the states.
Study design, duration and population
A hospital-based cross-sectional study was 
done under programme implementation. The 
study was conducted over 8-month period from 
February to October 2018. All diagnosed cases of 
diabetes mellitus who were aged 15 years and above, 
registered with and attending Diabetes Clinics in 
selected health facilities within the study period 
and who gave informed consent were included. 
Sampling technique and sample size 
determination
All diabetic clients attending DM clinics 
at the selected health facilities who met the 
inclusion criteria were included in the screening. 
They were recruited consecutively as they pre-
sented at clinic throughout the period of the 
study. A total of 3 457 patients were included in 
the study.
Procedure of screening 
The subjects were DM patients aged 15 years 
and above who have been registered in the DM 
clinic for care. Presumptive and diagnosed TB 
cases were screened for HIV in line with the na-
tional TB guidelines. The screening for TB was 
carried out at each patient’s visit (minimum of 
one month interval; however, each subject was 
reported only once during the project period) 
using a symptom-based standardised checklist. 
Referral of identified presumptive TB 
cases (among DM patients) to TB clinic 
Trained research assistants worked in colla-
boration with the staff at the DM clinics to: con-
duct a symptomatic TB screening for all eligible 
DM patients using appropriate tools (checklist), 
identify presumptive TB cases among those 
screened for TB; collect 2 sputum specimens from 
identified presumptive TB cases; send sputum 
specimens for GeneXpert diagnosis (second 
sputum specimen was equally processed if the 
first was negative), refer all diagnosed TB cases 
to TB clinic for treatment and record necessary 
data using tools. Good cooperation and colla-
boration were established between the 2 sets of 
staff working in the different service areas (DM 
and TB clinics). 
Data collection and analysis
Patient information was extracted from a stan-
dard globally used register and analysed. The re-
cords were filled by trained health workers to ensure 
good quality data. Double data entry was done to 
ensure accuracy. IBM Statistical Package for Social 
Sciences Version 21 was used for data entry, editing 
and analysis. Results were presented in tables. Yield 
[(new TB cases/total number with TB) × 100] and 
the number needed to screen (number of patients/ 
/new TB cases) were calculated. Mean, standard 
deviation, proportion and percentages were used 
as summary measures, where appropriate.
Ethical consideration
The Ethics and Research Advisory Commit-
tee of University of Nigeria Teaching Hospital 
(UNTH), Enugu approved the study. Approval 
was also obtained from the State TB Control 
Programme in six states selected for the project. 
Permission was equally obtained from heads of 
the facilities and written informed consent ob-
tained from the patients. Confidentiality of data 
was ensured in course of the research.
Results
Table 1 shows that a higher proportion of 
patients were aged ≥ 60 years 2 669 (77.2%) and 
with their mean age 59.86 years. Males were hi-
gher in proportion 2 277 (65.9%). They were pre-
dominantly civil/public servants — 1 428 (41.3%) 
and traders — 1 308 (37.8%). The majority had 
BMI of 25–29.9 kg/m2 1 340 (38.8%) followed by 
≥ 30 kg/m2 1 019 (29.5%). Only 22 (0.6%) currently 
smoked cigarettes or tobacco-based products. As 
well, only 3 (0.1%) tested positive for HIV. Most 
were type 2 DM 3 328 (96.3%). 
Table 2 shows that 6 386 patients attended 
the clinic within the 6 months of the study. Of 
this number, 3 457 (54.1%) were new patients or 
attended the clinic once. These were the patients 
further studies were based on. Presumptive cases 
were 221 (6.4%) out of which 184 (83.3%) were 
sent for Gene Xpert. In all 11 (0.3%) tested po-
sitive following screening (new cases), 16 (0.5%) 
were known cases (old cases), and 27 (0.8%) 
had TB (old and new cases) among the patients 
studied. Among the 11 subjects that were newly 
detected, all were sent for treatment. 
Table 3 shows that of the 3 457 patients stu-
died, yield was 40.7% and the number needed to 
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Table 2. Distribution of patients studied
Variables Formula* Value
A. Total number of DM patient visits over 6 months (including revisit) 6386
B. Number (%) of new DM patients studied (excluding revisit) [(B/A)×100] 3457 (54.1)
C. Number (%) of presumptive TB cases identified [(C/B) ×100] 221 (6.4)
D. Number (%) sent for GeneXpert test [(D/C) ×100] 184 (83.3)
E. Number (%) that with MTB detected (new cases) [(E/B) ×100] 11 (0.3)
F. Number placed on TB treatment 11
G. Number (%) of previously diagnosed (known) TB cases 16 (0.5)
H. Total number (%) of TB cases [(E+G)] 27 (0.8)
*What was computed to get value
DM — diabetes mellitus; TB — tuberculosis; MTB — Mycobacterium tuberculosis
Table 1. Characteristics of patients
Variables Frequency  
(n = 3457)
Percent (%)
Age (years)
< 60 788 22.8
≥ 60 2669 77.2
Mean (SD) 59.86 (12.86)
Gender
Male 2277 65.9
Female 1180 34.1
Occupation
Civil/public servant 1428 41.3
Trading/business 1309 37.9
Others 722 20.9
BMI 
< 18.5 102 3.0
18.5–24.9 996 28.7
25–29.9 1340 38.8
≥ 30 1019 29.5
Current smoker
Yes 22 0.6
No 3435 99.4
Type of DM 
1 129 3.7
2 3328 96.3
HIV 
Negative 3454 99.9
Positive 3 0.1
BMI — body mass index; DM — diabetes mellitus; HIV — human immuno-
deficiency virus
screen (NNS) for the yield was 315 patients. When 
disaggregated by characteristics, those aged < 60 
years had yield of 42.9% and NNS of 263, males 
had yield of 50.0% and NNS of 326, civil/public 
servants had yield of 37.5% and NNS of 476, those 
with BMI of < 18.5 had yield of 60.0% and NNS 
of 34, smokers had yield of 47.8% and NNS of 
313, type 2 DM patients had yield of 55.6% and 
NNS of 333 and those that were negative for HIV 
had yield of 38.5% and NNS of 345.
Discussion
The study reported that 11 DM patients or 
0.3% of them tested positive following screening 
(new cases). More findings were that yield of 
TB cases was 40.7% and the number needed to 
screen to make diagnosis of a TB case was 315 DM 
patients. This is revealing and encouraging as 
these identified cases would have been the foci 
of spread among unsuspecting public with their 
consequent effects. The findings can partly be 
explained by the large population size involved 
in the study. It also gave credence to innovations 
aimed at controlling the menace of the diseases. 
For instance, the Collaborative Framework for 
the Care and Control of Diabetes and Tuber-
culosis as launched by WHO and the Union 
have routine implementation of bi-directional 
screening of the DM and TB as one of the impor-
tant activities for control of TB [24]. In Nigeria 
where the methods of screening, recording and 
reporting DM and TB co-morbidity in routine 
health care settings are not well determined, 
these existing gaps can be addressed by such 
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Table 3. Distribution of patients yield and number needed to screen disaggregated by patient characteristics
Variables Number  
of patients
Total number 
with TB
Known TB 
cases
New TB cases Yield 
(%)
NNS
[A] [B] [C] [(C/B)×100] [A/C]
Overall 3457 27 16 11 40.7 315
Age (years)
< 60 788 7 4 3 42.9 263
≥ 60 2669 20 12 8 40.0 334
Gender
Female 1180 13 9 4 30.8 295
Male 2277 14 7 7 50.0 326
Occupation
Civil/public servant 1426 8 5 3 37.5 476
Trading/business 1309 13 9 4 30.8 328
Others 722 6 2 4 66.7 181
BMI 
< 18.5 102 5 2 3 60.0 34
18.5–24.9 996 10 5 5 50.0 193
25–29.9 1340 6 4 2 30.3 670
≥ 30 1019 4 3 1 25.0 1019
Current smoker
No 22 4 4 0 0.0 —
Yes 3435 23 12 11 47.8 313
DM type (n) 
1 129 3 3 0 0 —
2 3328 18 8 10 55.6 333
HIV status
Negative 3454 26 16 10 38.5 345
Positive 3 0 0 0 0 —
BMI — body mass index; DM — diabetes mellitus; NNS — number needed to screen; HIV — human immunodeficiency virus; TB — tuberculosis
activities like this programme implementation 
screening exercise.
Above all, diagnosis of TB disease is the 
entry point in the management of TB cases. Con-
sequently, early diagnosis through screening will 
lead to prompt commencement of chemotherapy; 
reduced transmission of the disease to unsuspec-
ting populace they come in contact with and 
ultimately, a positive impact on the control of the 
disease in the general population. 
Other previous studies supported findings 
from this study. In Taiwan, a screening done for 
pulmonary tuberculosis among the elderly with 
type 2 diabetes involving 3 087 patients detected 
7 (0.2%) patients who were positive for pulmo-
nary tuberculosis [26]. Similarly, in a symptom 
screening project in a  tertiary care hospital in 
south India, 12 cases were newly diagnosed 
of TB among 125 subjects that underwent TB 
investigation [27]. Another symptom screening 
research in Mexico detected 38 TB cases in 7 763 
diabetes patients [28]. In China, TB was diagnosed 
in 14 of 4 085 patients with DM following active 
screening [29, 30]. Findings from previous studies 
have shown that screening for active TB among 
diabetics could improve case detection just like 
in other populations susceptible to TB, including 
HIV-infected individuals, gold miners, and priso-
ners in developing countries [31]. 
The number of diabetics needed to screen 
to find one extra case of TB is directly related to 
the TB prevalence among that population. For 
instance, in areas with TB prevalence less than 
25 per 100 000 persons, at least 1 000 diabetic 
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individuals have to be screened to find one extra 
case of TB. With increasing prevalence, the num-
ber needed to screen to find one additional case 
of TB ranges from 4 to 442. This implies that the 
yield of screening increases with the prevalence 
of TB in that region [31]. Also, the population at-
tributed risk for TB from DM is dependent upon 
DM prevalence as evidenced in studies which 
documented that in populations with a higher 
incidence of TB, DM is a more important risk 
factor [32]. DM accounts for a small proportion of 
TB cases in settings such as Australia with a low 
incidence of TB [33]. This number was 14.8% in 
India and 25% in a Mexican setting due to higher 
incidence and prevalence [34].
None of those that tested positive for HIV 
had TB. This is good as it would be disastrous 
for a patient to have two recognized major thre-
ats to TB diagnosis and treatment outcome. This 
may be explained by the age distribution of the 
studied DM patients . Most were aged > 60 years 
of which most HIV positive subjects may not live 
as long as that due to either the comorbidities, 
drug-drug interactions or opportunistic infections 
as both DM and HIV infection reduce immunity. 
Human immunodeficiency virus infection is 
considered as the most potent risk factor for TB. 
Nevertheless, the high prevalence of DM in the 
world and its effect on TB burden is greater than 
that of HIV infection [7]. Even though HIV has 
been documented to be the strongest risk factor 
for TB at an individual level, DM is seen as most 
important at the population level. This indicates 
that having both will carry far-reaching health 
and economic implications.
Conclusions
The number of positive cases identified follo-
wing screening, yield of TB cases and the number 
needed to screen to make diagnosis of a TB case 
were encouraging. Active case finding in the form 
of screening as carried out in this study is needed 
to end the global TB. Such programme imple-
mentation should be encouraged and advanced 
to reduce scourge of TB and its co-morbidities.
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